(111 days)
Not Found
No
The summary describes a device that performs standard electrical measurements and stimulation functions for pacing leads. There is no mention of AI or ML algorithms for analysis, interpretation, or decision-making.
Yes.
The device is indicated for "temporary diagnostic and therapeutic application," including emergency stimulation and high-rate (burst) stimulation. It can also "temporarily take over the functions of a cardiac pacemaker" during an implantation procedure. These functions directly involve treating or managing a medical condition (cardiac rhythm issues), qualifying it as a therapeutic device.
Yes
The device is described as a "pacing system analyzer" used for "evaluation of the integrity and most beneficial placement of stimulation leads" which involves measuring electrical impedance, capturing heart rhythm, and measuring P and R wave amplitudes and corresponding slew rates. These are diagnostic functions. Additionally, the intended use explicitly states "limited to temporary diagnostic and therapeutic application."
No
The device description explicitly details hardware components such as a touch screen, keys, receptacles for leads, a terminal for surface ECG, LED indicators, an integrated rechargeable battery, a backup battery, and a robust enclosure. It is a physical device with integrated software, not a software-only device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for "stimulation lead system analysis prior or during implantation of an electrical stimulator (pacemaker, pulse generator), for emergency stimulation and for high-rate (burst) stimulation limited to temporary diagnostic and therapeutic application." This describes a device used in vivo (within the body) to interact with and analyze the electrical activity of the heart and the performance of implanted leads.
- Device Description: The description details a "portable pacing system analyzer" that connects to stimulation leads or extension cables and a surface ECG. It measures electrical parameters related to the heart's intrinsic activity and the ability to stimulate the heart. These are all in vivo measurements and functions.
- Anatomical Site: The anatomical site is the "Heart," which is an in vivo location.
- IVD Definition: In vitro diagnostics are tests performed on biological samples (like blood, urine, or tissue) outside of the body to detect diseases, conditions, or infections. This device does not perform such tests on biological samples.
The device is clearly designed for direct interaction with the patient's heart and implanted leads during a medical procedure, which is characteristic of an in vivo medical device, not an IVD.
N/A
Intended Use / Indications for Use
This device is indicated for use in stimulation lead system analysis prior or during implantation of an electrical stimulator (pacemaker, pulse generator), for emergency stimulation and for high-rate (burst) stimulation limited to temporary diagnostic and therapeutic application.
Product codes (comma separated list FDA assigned to the subject device)
DTE, DTA
Device Description
PSA™ Series devices are portable pacing system analyzers, which are intended to be used for the evaluation of the integrity and most beneficial placement of stimulation leads. The integrity of a stimulation lead system is characterized by its electrical impedance, the measurement results of which shall meet the specifications of the manufacturer of the lead system. The most beneficial placement of a stimulation lead system is determined by the ability of the PSA Series device to capture the heart rhythm (successful stimulation) and to measure reasonable high amplitudes of P and/or R waves and corresponding slew rates. The PSA™ Series encompasses a single-channel device (PSA 100) and dual-channel device (PSA 200) with each channel employing a differential stimulation output and a differential sensing input. Stimulation leads or extension cables are connected to patented receptacles accommodating pins of 0.9 ... 2 mm or Hypertronics ™ style sockets. In addition to the aforementioned intra-cardiac channels, a PSA Series device offers an additional channel and corresponding terminal for a 5-lead surface ECG.
The user interface is divided into a touch screen and an array of four keys dedicated to the functions
• On / Off Turn device on or off
• Emergency Switch to emergency stimulation mode
• High-Rate Switch to High-Rate stimulation mode
• Home Return to main menu
The user monitors device measurements, heart activity and device status through the touch screen and LED indicators. Functions provided by PSA™ series pacing system analyzers are organized into so called applications such as (availability depending on PSA Series model):
• 1/A Single-chamber stimulation (Channel 1/A)
• 2/RV Single-chamber stimulation (Channel 2/RV)
• DDD Atrioventricular (dual-chamber) stimulation
• UHS Burst stimulation (Universal Heart Stimulator)
By choosing one application, the (touch) screen displays all functions and information relevant to the specific application. The screen displays with minimal delay a marker signal and up to four signal waveforms all of which a user can select from the group of up to three IEGM signal waveforms (1/A, 2/RV; availability depending on PSA model) and seven surface ECG standard vectors (I, II, III, aVR, aVL, aVF, V).
The device provides or facilitates the following measurements:
• Sensing of intrinsic events of the heart:
• P/R wave amplitudes and slew rate
• Rates (PP, RR interval)
• Intrinsic AV delay (antegrade conduction time)
• Retrograde conduction time
• Wenckebach point (2:1 conduction)
• Stimulation of the heart
• Capture threshold in up to 2 chambers
• Lead impedances
• Burst stimulation
During an implantation procedure a PSA™ Series device can temporarily take over the functions of a cardiac pacemaker. Measurement results can be stored to a virtual print-out page, which upon completion of all measurements is transmitted wirelessly to a separate printer or computer. User-configurable settings for general use of the device and individual applications are stored in non-volatile memory.
The HIGH-RATE function (dedicated key below the touch screen) provides bust stimulation at rates variable from 70 to 1,000 ppm for terminating atrial and ventricular tachycardia. The (optional) UHS application is special form of the high rate function. Within the UHS application, the user can program a train of burst prior to clinical application, which is also referred to as programmable electrical stimulation (PES). Pressing the EMERGENCY key (dedicated key below the touch screen) immediately initiates an emergency stimulation (VVI, 60 ppm, 7.5 V, 1.0 ms). Pressing the HOME key allows the user to return to the home screen (main menu). The device can operate from line power or the integrated rechargeable battery which provides up to 4 hours of continuous operation. A medical-grade AC power supply is part of the delivery unit. An integrated backup battery maintains stimulation in the unlikely event of a failure of the integrated rechargeable battery or AC power. The robust device enclosure is protected against accidental fluid spill.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance Test- Bench: Purpose of bench testing is to verify the performance of the device under test with respect to employing the intended stimulation (pacing) mode (including high-rate and emergency modes), stimulation (pacing), sensing and timing parameters, the ability of the device to detect faulty conditions, and with respect to the predicate device.
Stimulation Modes: Bench testing using an Interstim II heart simulator verified that the device under test performed the following stimulation modes as intended: AAI, VVI, DDD, VDD, DDI and VDI. Bench testing further verify that the functions high rate pacing and emergency pacing perform as intended.
Stimulation, Sensing and Timing Parameters: Parameters were measured with the Osypka SMS 1000, a custom-build computer-assisted test system that consists of the PC card EKG2GEN (a specialized and combined ADC/DAC card) and the PC program PACE. It is part of the supervised measuring equipment of the company and used for final measurements of external pacemakers and pacing system analyzers. The test system fulfills the requirements of the applicable standards for measuring pacemaker parameters and is used otherwise in the production process of pacemakers.
Stimulation Parameters: Pulse Amplitude (Verification for pulse amplitude of 0.1...10 V for each stimulation channel 1/A, 2/RV), Pulse Width (Verification for pulse widths of 0.1...2.5 ms for each stimulation channel 1/A, 2/RV), Pulse Rate (Verification for pulse rates of 30...220 ppm for each stimulation channel 1/A, 2/RV), Sensitivity (Verification for sensitivity threshold of 0.2...20 mV for each sensing channel 1/A, 2/RV).
Timing: AV Delay (Verification for AV Delay settings of 10...400 ms measured between channel 1/A and 2/RV), Refractory Periods (Verification for refractory period settings of 250...500 ms for each channel 1/A, 2/RV).
Test of Device Behavior Under Fault Conditions: The device under test was exposed to the following device and application related faults and reacted as intended: Start-up self-test failed, Electrode impedance to low (short circuit), Electrode impedance to high (open lead), EGM signal noise, Battery low, Battery empty, Attempt to switch device off during stimulation, High Rate pacing timeout atrium.
Essential Performance Comparison Testing: The device under test was compared to its predicate device with respect to the following parameters: Heart Rate / RR Interval, P/R Wave Amplitude, Lead Impedance, Retrograde Conduction Time, Wenckebach Point. The test results demonstrated a substantial equivalence between the device under test and the predicate device.
Performance Test - Clinical: The objective of this clinical investigation is to determine whether Osypka Medical's PSA pacing system analyzer (referred to hence forth as the "PSA") is safe and effective within the scope of its intended use. This objective will be met by the following clinical investigations conducted at two clinical sites in Hamburg, Germany. The clinical investigations were conducted during routine pacemaker implantation procedure in the operating room:
Intrinsic measurement comparisons:
Method: PSA's measurements of the patient's intrinsic values will be compared to the Biotronik's ERA 300 dual chamber pacing system analyzer (referred to hence forth as the "ERA") and Medtronic Carelink 2290 Analyzer (referred to hence forth as the "M2290") performed on the same patient in consecutive order where these measurements are appropriate. PSA, ERA, and M2290 parameters analyzed include heart rate (PP/RR intervals), amplitude, slew rate, impedance, anterograde conductance (AV time) and retrograde conductance (VA time). Data from 17 patients were used in this analysis. Although the M2290 is not used as a predicate device, it serves as a reference when differences between the PSA and ERA need further explanation.
Results: Acceptance criteria were established for each parameter compared across devices. Based on the data analyzed from 17 patients (15 atriums and 18 ventricles), the PSA fulfilled the acceptance criteria for each parameter and thus can be considered equivalent to the ERA.
Stimulation and Sensing Evaluation:
Method: ECG tracing are analyzed beat by beat while the PSA paces in order to determine effective sensing and pacing. Effective sensing is defined here as inhibition of the atrial and/or ventricle pacemaker stimulus in the presence of P waves and R waves, respectively. Effective pacing is defined here as effective atrial and/or ventricle stimulation with their respective time domains. ECG tracings and physician notes will be used to determine whether an adverse event occurred while the PSA was applied to the patient.
Results: No adverse events occurred while PSA was applied to patient. PSA correctly recognized atrial and ventricular heart activity and inhibited in 364/364 (100%) cardiac cycles recorded. PSA correctly caused atrial and/or ventricle capture in 1,621/1,621 (100%) of cardiac cycles recorded. PSA is considered safe and effective.
Conclusion: Demonstration of substantial equivalence between the PSA™ Series devices (PSA 200™ and PSA 100™), and its predicate device established from clinical and non-clinical performance data.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
PSA correctly recognized atrial and ventricular heart activity and inhibited in 364/364 (100%) cardiac cycles recorded. PSA correctly caused atrial and/or ventricle capture in 1,621/1,621 (100%) of cardiac cycles recorded.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3600 External pacemaker pulse generator.
(a)
Identification. An external pacemaker pulse generator (EPPG) is a prescription device that has a power supply and electronic circuits that produce a periodic electrical pulse to stimulate the heart. This device, which is used outside the body, is used as a temporary substitute for the heart's intrinsic pacing system until a permanent pacemaker can be implanted, or to control irregular heartbeats in patients following cardiac surgery or a myocardial infarction. The device may have adjustments for impulse strength, duration, R-wave sensitivity, and other pacing variables.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Appropriate analysis/testing must validate electromagnetic compatibility (EMC) within a hospital environment.
(2) Electrical bench testing must demonstrate device safety during intended use. This must include testing with the specific power source (
i.e., battery power, AC mains connections, or both).(3) Non-clinical performance testing data must demonstrate the performance characteristics of the device. Testing must include the following:
(i) Testing must demonstrate the accuracy of monitoring functions, alarms, measurement features, therapeutic features, and all adjustable or programmable parameters as identified in labeling;
(ii) Mechanical bench testing of material strength must demonstrate that the device and connection cables will withstand forces or conditions encountered during use;
(iii) Simulated use analysis/testing must demonstrate adequate user interface for adjustable parameters, performance of alarms, display screens, interface with external devices (
e.g. data storage, printing), and indicator(s) functionality under intended use conditions; and(iv) Methods and instructions for cleaning the pulse generator and connection cables must be validated.
(4) Appropriate software verification, validation, and hazard analysis must be performed.
(5) Labeling must include the following:
(i) The labeling must clearly state that these devices are intended for use in a hospital environment and under the supervision of a clinician trained in their use;
(ii) Connector terminals should be clearly, unambiguously marked on the outside of the EPPG device. The markings should identify positive (+) and negative (−) polarities. Dual chamber devices should clearly identify atrial and ventricular terminals;
(iii) The labeling must list all pacing modes available in the device;
(iv) Labeling must include a detailed description of any special capabilities (
e.g., overdrive pacing or automatic mode switching); and(v) Appropriate electromagnetic compatibility information must be included.
0
APR 0 9 2013
K123916 510(k) Summary
| Submitter: | Osypka Medical, Inc.
7463 Draper Avenue, La Jolla, CA 92037 |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact
Person: | Markus Osypka, Ph.D., President
Osypka Medical, Inc.
7463 Draper Avenue, La Jolla, CA 92037 |
| Device
Trade
Name: | PSA™ Series, PSA 200™ and PSA 100™ Pacing System Analyzer |
| Predicate
Device: | Biotronik ERA 300 Dual Chamber Pacing System Analyzer (K964190) |
| Device
Description: | PSA™ Series devices are portable pacing system analyzers, which are intended
to be used for the evaluation of the integrity and most beneficial placement of
stimulation leads. |
| | The integrity of a stimulation lead system is characterized by its electrical
impedance, the measurement results of which shall meet the specifications of the
manufacturer of the lead system. |
| | The most beneficial placement of a stimulation lead system is determined by the
ability of the PSA Series device to capture the heart rhythm (successful
stimulation) and to measure reasonable high amplitudes of P and/or R waves and
corresponding slew rates. |
| | The PSA™ Series encompasses a single-channel device (PSA 100) and dual-
channel device (PSA 200) with each channel employing a differential stimulation
output and a differential sensing input. Stimulation leads or extension cables are
connected to patented receptacles accommodating pins of 0.9 ... 2 mm or
Hypertronics ™ style sockets. In addition to the aforementioned intra-cardiac
channels, a PSA Series device offers an additional channel and corresponding
terminal for a 5-lead surface ECG. |
1
| Device
Description
| (continued): | The user interface is divided into a touch screen and an array of four keys dedicated to the functions | ||
|---|---|---|---|
| • On / Off | Turn device on or off | ||
| • Emergency | Switch to emergency stimulation mode | ||
| • High-Rate | Switch to High-Rate stimulation mode | ||
| • Home | Return to main menu | ||
| The user monitors device measurements, heart activity and device status through the touch screen and LED indicators. | |||
| Functions provided by PSA™ series pacing system analyzers are organized into so called applications such as (availability depending on PSA Series model): | |||
| • 1/A | Single-chamber stimulation (Channel 1/A) | ||
| • 2/RV | Single-chamber stimulation (Channel 2/RV) | ||
| • DDD | Atrioventricular (dual-chamber) stimulation | ||
| • UHS | Burst stimulation (Universal Heart Stimulator) | ||
| By choosing one application, the (touch) screen displays all functions and information relevant to the specific application. The screen displays with minimal delay a marker signal and up to four signal waveforms all of which a user can select from the group of up to three IEGM signal waveforms (1/A, 2/RV; availability depending on PSA model) and seven surface ECG standard vectors (I, II, III, aVR, aVL, aVF, V). | |||
| The device provides or facilitates the following measurements: | |||
| • Sensing of intrinsic events of the heart: | |||
| • P/R wave amplitudes and slew rate | |||
| • Rates (PP, RR interval) | |||
| • Intrinsic AV delay (antegrade conduction time) | |||
| • Retrograde conduction time | |||
| • Wenckebach point (2:1 conduction) | |||
| • Stimulation of the heart | |||
| • Capture threshold in up to 2 chambers | |||
| • Lead impedances | |||
| • Burst stimulation | |||
| During an implantation procedure a PSA™ Series device can temporarily take over the functions of a cardiac pacemaker. | |||
| Measurement results can be stored to a virtual print-out page, which upon completion of all measurements is transmitted wirelessly to a separate printer or computer. User-configurable settings for general use of the device and individual applications are stored in non-volatile memory. |
2
| Device
Description
(continued): | The HIGH-RATE function (dedicated key below the touch screen) provides bust
stimulation at rates variable from 70 to 1,000 ppm for terminating atrial and
ventricular tachycardia.
The (optional) UHS application is special form of the high rate function. Within the
UHS application, the user can program a train of burst prior to clinical application,
which is also referred to as programmable electrical stimulation (PES).
Pressing the EMERGENCY key (dedicated key below the touch screen)
immediately initiates an emergency stimulation (VVI, 60 ppm, 7.5 V, 1.0 ms).
Pressing the HOME key allows the user to return to the home screen (main
menu).
The device can operate from line power or the integrated rechargeable battery
which provides up to 4 hours of continuous operation. A medical-grade AC power
supply is part of the delivery unit.
An integrated backup battery maintains stimulation in the unlikely event of a
failure of the integrated rechargeable battery or AC power.
The robust device enclosure is protected against accidental fluid spill. | |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Intended
Use: | This device is indicated for use in stimulation lead system analysis prior or during
implantation of an electrical stimulator (pacemaker, pulse generator), for
emergency stimulation and for high-rate (burst) stimulation limited to temporary
diagnostic and therapeutic application. | |
| Performance
Test- Bench: | Purpose of bench testing is to verify the performance of the device under test with
respect to employing the intended stimulation (pacing) mode (including high-rate
and emergency modes), stimulation (pacing), sensing and timing parameters, the
ability of the device to detect faulty conditions, and with respect to the predicate
device. | |
| | Stimulation Modes | |
| | Bench testing using an Interstim II heart simulator verified that the device under
test performed the following stimulation modes as intended: AAI, VVI, DDD, VDD,
DDI and VDI. | |
| | Bench testing further verify that the functions high rate pacing and emergency
pacing perform as intended. | |
| | Stimulation, Sensing and Timing Parameters | |
| | Parameters were measured with the Osypka SMS 1000, a custom-build
computer-assisted test system that consists of the PC card EKG2GEN (a
specialized and combined ADC/DAC card) and the PC program PACE. It is part
of the supervised measuring equipment of the company and used for final
measurements of external pacemakers and pacing system analyzers. The test
system fulfills the requirements of the applicable standards for measuring
pacemaker parameters and is used otherwise in the production process of
pacemakers. | |
| | Parameter | Bench Testing |
| Stimulation
Parameters | Pulse Amplitude | Verification for pulse amplitude of 0.1...10 V
for each stimulation channel 1/A, 2/RV |
| | Pulse Width | Verification for pulse widths of 0.1...2.5 ms
for each stimulation channel 1/A, 2/RV |
| | Pulse Rate | Verification for pulse rates of 30...220 ppm
for each stimulation channel 1/A, 2/RV |
| | Sensitivity | Verification for sensitivity threshold of
0.2...20 mV for each sensing channel 1/A,
2/RV |
| Timing | AV Delay | Verification for AV Delay settings of 10...400
ms measured between channel 1/A and
2/RV |
| | Refractory
Periods | Verification for refractory period settings of
250...500 ms for each channel 1/A, 2/RV |
| Test of Device Behavior Under Fault Conditions | | |
| The device under test was exposed to the following device and application related
faults and reacted as intended: | | |
| • Start-up self-test failed | | |
| • Electrode impedance to low (short circuit) | | |
| • Electrode impedance to high (open lead) | | |
| • EGM signal noise | | |
| • Battery low | | |
| • Battery empty | | |
| • Attempt to switch device off during stimulation | | |
| • High Rate pacing timeout atrium | | |
| Essential Performance Comparison Testing | | |
| The device under test was compared to its predicate device with respect to the
following parameters: | | |
| • Heart Rate / RR Interval | | |
| • P/R Wave Amplitude | | |
| • Lead Impedance | | |
| • Retrograde Conduction Time | | |
| • Wenckebach Point | | |
| The test results demonstrated a substantial equivalence between the device
under test and the predicate device. | | |
3
4
| Performance
Test-
Clinical | Performance Test - Clinical
The objective of this clinical investigation is to determine whether Osypka
Medical's PSA pacing system analyzer (referred to hence forth as the "PSA") is
safe and effective within the scope of its intended use. |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | This objective will be met by the following clinical investigations conducted at two
clinical sites in Hamburg, Germany. The clinical investigations were conducted
during routine pacemaker implantation procedure in the operating room: |
| | Intrinsic measurement comparisons |
| | Method |
| | PSA's measurements of the patient's intrinsic values will be compared to the
Biotronik's ERA 300 dual chamber pacing system analyzer (referred to hence
forth as the "ERA") and Medtronic Carelink 2290 Analyzer (referred to hence forth
as the "M2290") performed on the same patient in consecutive order where these
measurements are appropriate. |
| | PSA, ERA, and M2290 parameters analyzed include heart rate (PP/RR intervals),
amplitude, slew rate, impedance, anterograde conductance (AV time) and
retrograde conductance (VA time). Data from 17 patients were used in this
analysis. Although the M2290 is not used as a predicate device, it serves as a
reference when differences between the PSA and ERA need further explanation. |
| | Results |
| | Acceptance criteria were established for each parameter compared across
devices. Based on the data analyzed from 17 patients (15 atriums and 18
ventricles), the PSA fulfilled the acceptance criteria for each parameter and thus
can be considered equivalent to the ERA. |
| | Stimulation and Sensing Evaluation |
| | Method |
| | ECG tracing are analyzed beat by beat while the PSA paces in order to determine
effective sensing and pacing. Effective sensing is defined here as inhibition of the
atrial and/or ventricle pacemaker stimulus in the presence of P waves and R
waves, respectively. Effective pacing is defined here as effective atrial and/or
ventricle stimulation with their respective time domains. ECG tracings and
physician notes will be used to determine whether an adverse event occurred
while the PSA was applied to the patient. |
| | Results |
| | No adverse events occurred while PSA was applied to patient. PSA correctly
recognized atrial and ventricular heart activity and inhibited in 364/364 (100%)
cardiac cycles recorded. PSA correctly caused atrial and/or ventricle capture in
1,621/1,621 (100%) of cardiac cycles recorded. PSA is considered safe and
effective. |
| Conclusion: | Demonstration of substantial equivalence between the PSA™ Series devices
(PSA 200™ and PSA 100™), and its predicate device established from clinical
and non-clinical performance data. |
5
Image /page/5/Picture/0 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle or bird-like symbol with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" is arranged in a circular fashion around the symbol.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 9, 2013
Dr. Markus J. Osypka Osypka Medical, Inc 7855 Ivanhoe Avenue, Suite 226 La Jolla, California 92037
Re: K123916
Trade Name: PSATN Series Pacing System Analyzer (PSA 100TM and PSA 200™) Regulation Number: 21 CFR 870.3600 Regulation Name: External Pacemaker Pulse Generator Regulatory Class: Class III Product Code: DTE, DTA Dated: March 1, 2013 Received: March 4, 2013
Dear Dr. Osypka:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were legally on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. Please note: If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit/tray. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
6
Page 2 - Markus J. Osypka
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Owen PMEaris -S
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
・
Indications for Use
K123916 510(k) Number (if known):
Device Names:
OSYPKA MEDICAL
PSA TM Series Pacing System Analyzer PSA 100™ and PSA 200™
CARDIOTRONIC PSA ™ Series
Pacing System Analyzer PSA 100™ and PSA 200™
Indications for Use:
This device is indicated for use in stimulation lead system analysis prior or during implantation of an electrical stimulator (pacemaker, pulse generator), for emergency stimulation and for high-rate (burst) stimulation limited to temporary diagnostic and therapeutic application.
Prescription Use × (Part 21 CFR 801 Subpart D)
AND / OR
Over-The-Counter-Use (Part 21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Page 1 of 1